drugset / Trial / NCT03007446

The Study of Conversion Surgery for Apatinib in Combination With SOX for Patients With Unresectable Gastric Cancer

NCT03007446 ↗

Phase 2 Unknown 20 enrolled Chinese PLA General Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is a Prospective,Single-center,Single-arm,Open-label exploratory clinical trial evaluating the efficacy and safety of Conversion Surgery for Apatinib plus SOX for patients with unresectable gastric cancer.

Timeline

Start
2016-11
Primary completion
2018-11
Completion
2018-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxaliplatin Small molecule 130 mg/m2 Intravenous
Subject Rivoceranib Small molecule 500 mg —
Subject S-1 Small molecule 40 mg —

Indications